Share on StockTwits

Immune Design Corp’s (NASDAQ:IMDZ) quiet period will expire on Tuesday, September 2nd. Immune Design Corp had issued 5,000,000 shares in its IPO on July 24th, Analyst Ratings Network.com reports. The total size of the offering was $60,000,000 based on an initial share price of $12.00. During Immune Design Corp’s quiet period, underwriters and any insiders that worked on the IPO are prevented from issuing any research reports for the company because of SEC regulations. Following the expiration of the company’s quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.

A number of analysts have recently weighed in on IMDZ shares. Analysts at Leerink Swann initiated coverage on shares of Immune Design Corp in a research note on Tuesday, August 19th. They set an “outperform” rating on the stock. Separately, analysts at Wells Fargo & Co. initiated coverage on shares of Immune Design Corp in a research note on Monday, August 18th. They set an “outperform” rating on the stock. Finally, analysts at Jefferies Group initiated coverage on shares of Immune Design Corp in a research note on Monday, August 18th. They set a “buy” rating and a $15.00 price target on the stock.

Immune Design Corp (NASDAQ:IMDZ) traded up 1.69% on Monday, hitting $12.01. 20,539 shares of the company’s stock traded hands. Immune Design Corp has a 1-year low of $11.51 and a 1-year high of $12.81. The stock’s 50-day moving average is $12.11 and its 200-day moving average is $12.11. The company’s market cap is $189.4 million.

Immune Design Corp is a clinical-stage immunotherapy company. The Company has engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells (NASDAQ:IMDZ), to fight cancer.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.